Glycoprotein B Vaccine Is Capable of Boosting Both Antibody and CD4 T-Cell Responses to Cytomegalovirus in Chronically Infected Women

Por Sabbaj, Steffanie, Pass, Robert F., Goepfert, Paul A., Pichon, Sylvie
Publicado em 2011

1113 Safety and Efficacy of a Cytomegalovirus Glycoprotein B (gB) Vaccine in Adolescent Girls

Por Bernstein, David I., Callahan, S. Todd, Munoz-Rivas, Flor, Rupp, Rick, Edwards, Kathryn, Stanberry, Lawrence R., Pichon, Sylvie, Amegashie, Cyrille, Bellamy, Abbie R.
Publicado no Open Forum Infect Dis (2014)

Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation

Por Baraniak, Ilona, Gomes, Ariane C., Sodi, Isabella, Langstone, Toby, Rothwell, Emily, Atkinson, Claire, Pichon, Sylvie, Piras-Douce, Fabienne, Griffiths, Paul D., Reeves, Matthew B.
Publicado no EBioMedicine (2019)

Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia

Por Baraniak, Ilona, Kropff, Barbara, McLean, Gary R, Pichon, Sylvie, Piras-Douce, Fabienne, Milne, Richard S B, Smith, Colette, Mach, Michael, Griffiths, Paul D, Reeves, Matthew B
Publicado no J Infect Dis (2018)

Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies

Por Baraniak, Ilona, Kropff, Barbara, Ambrose, Lyn, McIntosh, Megan, McLean, Gary R., Pichon, Sylvie, Atkinson, Claire, Milne, Richard S. B., Mach, Michael, Griffiths, Paul D., Reeves, Matthew B.
Publicado no Proc Natl Acad Sci U S A (2018)

Safety and Efficacy of a Cytomegalovirus Glycoprotein B (gB) Vaccine in Adolescent Girls: a Randomized Clinical Trial

Por Bernstein, David I., Munoz, Flor M., Callahan, S. Todd, Rupp, Richard, Wootton, Susan H., Edwards, Kathryn M., Turley, Christine B., Stanberry, Lawrence R., Patel, Shital M., Mcneal, Monica M., Pichon, Sylvie, Amegashie, Cyrille, Bellamy, Abbie R
Publicado no Vaccine (2015)

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

Por Griffiths, Paul D, Stanton, Anna, McCarrell, Erin, Smith, Colette, Osman, Mohamed, Harber, Mark, Davenport, Andrew, Jones, Gareth, Wheeler, David C, O'Beirne, James, Thorburn, Douglas, Patch, David, Atkinson, Claire E, Pichon, Sylvie, Sweny, Paul, Lanzman, Marisa, Woodford, Elizabeth, Rothwell, Emily, Old, Natasha, Kinyanjui, Ruth, Haque, Tanzina, Atabani, Sowsan, Luck, Suzanne, Prideaux, Steven, Milne, Richard SB, Emery, Vincent C, Burroughs, Andrew K
Publicado em 2011